SG Americas Securities LLC bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 12,358 shares of the company’s stock, valued at approximately $126,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in iTeos Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after purchasing an additional 9,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in iTeos Therapeutics by 14.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares during the last quarter. Candriam S.C.A. acquired a new position in iTeos Therapeutics during the 2nd quarter valued at about $7,558,000. Acadian Asset Management LLC acquired a new position in iTeos Therapeutics during the 1st quarter valued at about $3,337,000. Finally, Clearline Capital LP acquired a new position in iTeos Therapeutics during the 2nd quarter valued at about $2,328,000. Institutional investors and hedge funds own 97.16% of the company’s stock.
iTeos Therapeutics Trading Up 1.4 %
NASDAQ:ITOS opened at $8.72 on Friday. The stock has a market capitalization of $318.45 million, a PE ratio of -2.91 and a beta of 1.36. The firm’s 50 day moving average is $12.64 and its 200 day moving average is $14.22. iTeos Therapeutics, Inc. has a 12 month low of $8.55 and a 12 month high of $18.75.
Analysts Set New Price Targets
Several equities analysts have commented on ITOS shares. Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Wedbush reissued an “outperform” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Monday, September 16th.
View Our Latest Stock Analysis on ITOS
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Read More
- Five stocks we like better than iTeos Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Dividend Payout Ratio Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.